
Amy Fowler Therapy Expands Services with Move to New State-of-the-Art Office Location in Fort Worth
Licensed Professional Counselor Associate brings specialized child, teen, women's, and couples therapy services to enhanced therapeutic space designed for healing and growth
FORT WORTH, TX – May 30, 2025 – Amy Fowler Therapy, a leading private practice specializing in counseling services for children, teens, women, and couples, announces its relocation to a new, purpose-built office at 3348 Peden Rd., Suite 407, Fort Worth, TX 76179. The move represents a significant expansion of the practice's ability to serve the North Texas community with enhanced therapeutic environments specifically designed to meet the unique needs of each client population.
Amy Fowler, a Licensed Professional Counselor Associate (LPCA) with over 17 years of experience working with children and adolescents and more than 10 years counseling women, has created a therapeutic space that reflects her commitment to providing exceptional mental health care in a welcoming, judgment-free environment. The new location significantly expands the practice's capacity to serve families throughout Fort Worth, Haslet, Keller, Saginaw, and surrounding communities.
The new office features thoughtfully designed spaces that cater to the diverse needs of Amy Fowler Therapy's clientele. The facility includes a spacious family waiting room where parents and caregivers can feel comfortable while their children receive treatment. This welcoming area acknowledges the important role families play in the therapeutic process and provides a relaxed environment for pre- and post-session discussions.
The centerpiece of the new location is a large, versatile counseling office that incorporates specialized sections for different therapeutic modalities. Understanding that children often express themselves best through play, the space includes dedicated areas for play therapy, allowing children to explore their emotions, thoughts, and experiences through activities like drawing, storytelling, and role-playing. Additionally, the office features a designated art therapy section, providing children with creative outlets to process their feelings and develop coping strategies in ways that traditional talk therapy might not achieve.
For adult clients, particularly women seeking counseling services and couples working to strengthen their relationships, the new space offers a calming environment specifically designed to promote healing and personal growth. Amy's extensive experience helping women overcome relationship challenges, parenting issues, self-identity concerns, workplace struggles, and grief, combined with her work helping couples navigate communication breakdowns, trust issues, emotional distance, and life transitions, has informed the creation of this therapeutic space, ensuring that every element supports the journey toward wholeness and emotional well-being.
Amy Fowler holds a Master of Education in Counseling from Dallas Baptist University and has particular expertise working with special needs populations, including learning disabilities, ADHD, autism spectrum disorder, and emotional disturbance. Her background as a special education classroom teacher and elementary school counselor in Keller ISD for two decades provides her with unique insights into child development and the challenges families face.
The practice addresses a wide range of issues through evidence-based therapeutic techniques, including Cognitive Behavioral Therapy (CBT), play therapy, and Solution Focused Therapy (SFT). Common areas of treatment include anxiety, depression, ADHD, autism spectrum disorders, learning disabilities, trauma, behavioral issues, and family relationship challenges.
For women clients, Amy provides specialized support for anxiety and depression, PTSD and trauma recovery, menopause and hormonal changes, self-identity and self-worth issues, relationship challenges, and grief and loss.
For couples, she offers marriage counseling to help partners strengthen communication, rebuild trust, resolve conflicts, navigate parenting stress, and work through life transitions including healing from infidelity or emotional betrayal. Her approach combines evidence-based techniques to create a supportive and judgment-free environment where women and couples can develop effective coping strategies, build stronger relationships, and improve overall emotional well-being.
The new location reflects Amy Fowler Therapy's commitment to making quality mental health care accessible to families and couples in the North Texas area. The practice operates on a private-pay model with individual sessions priced at $115 for 50-minute sessions, and marriage counseling sessions at $125 for 50-minute sessions. The practice accepts HSA and FSA cards to help families manage healthcare costs. For families seeking child therapy services, an initial 90-minute parent intake session is required at $125, providing a comprehensive foundation for developing effective treatment plans.
Amy's approach emphasizes collaboration with parents, teachers, and other healthcare professionals to ensure comprehensive support for each client. This collaborative care model ensures that children receive consistent support across different environments, promoting their overall well-being and success in academic, social, and family settings.
The expansion comes at a time when mental health awareness and the need for accessible therapeutic services continue to grow throughout Texas communities. Mental health is a crucial part of a child's overall well-being, and early intervention can prevent minor issues from becoming major disorders, helping children lead healthier and more fulfilling lives. Similarly, for women juggling multiple roles and responsibilities, professional therapy provides crucial support to navigate life's challenges and foster personal growth. For couples facing relationship challenges, professional counseling offers tools to strengthen communication, rebuild trust, and create healthier partnerships.
Amy's approach to therapy is rooted in radical empathy, ensuring that every client feels deeply understood and supported. She is dedicated to creating a safe, nurturing environment where individuals can explore their emotions and challenges without judgment.
Amy Fowler Therapy is a private counseling practice serving children, teens, women, and couples in the Fort Worth area. Amy Fowler is a Licensed Professional Counselor Associate with specialized training in Trust-Based Relational Intervention for Trauma, Crisis Prevention Intervention, and Critical Incident Stress Debriefing. She holds a Bachelor of Science from Texas Christian University and a Master of Education from Dallas Baptist University, with additional certification from Lamar University.
The practice serves clients from throughout the North Texas region, including Fort Worth, Haslet, Keller, Saginaw, Rhome, and surrounding communities. Amy Fowler Therapy is committed to helping individuals and families find wholeness through compassionate, evidence-based therapeutic interventions.
Contact Information:
Amy Fowler Therapy3348 Peden Rd., Suite 407
Fort Worth, TX 76179

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Larkspur Biosciences Announces Discovery of LRK-4189, a First-in-Class Degrader of the Lipid Kinase PIP4K2C, for the Treatment of Microsatellite Stable (MSS) Colorectal Cancer at the ACS Fall 2025 Meeting
First-in-human, Phase 1 Study of LRK-4189 to Begin in the Fourth Quarter CAMBRIDGE, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Larkspur Biosciences, a company pioneering a new wave in cancer therapy that destroys tumors by targeting cancer cell fitness, today announced the discovery of LRK-4189, a first-in-class degrader of the lipid kinase PIP4K2C for the treatment of microsatellite stable (MSS) colorectal cancer (CRC) and other solid tumors. The announcement was made at a presentation Larkspur was invited to give at the prestigious MEDI First Time Disclosures: Breakthroughs on New Medicines session at ACS Fall 2025, a meeting of the American Chemical Society in Washington, DC. Cancer cells maintain their fitness by developing survival adaptations that foster escape from intrinsic and extrinsic mechanisms of cell death in conditions of stress. Phosphatidylinositol 5-phosphate 4-kinase, type II, gamma (PIP4K2C) is a lipid kinase associated with poor outcomes in a range of cancers including CRC and breast cancers. PIP4K2C is co-opted by cancer cells to increase their fitness by evading immune surveillance and adapting to stress. 'Genetic studies have long highlighted PIP4K2C as a key player in cancer stress adaptation, but its extremely low kinase activity made it resistant to conventional inhibition approaches,' said Catherine Sabatos-Peyton, PhD, CEO of Larkspur Biosciences. 'With our novel degrader, LRK-4189, we've finally unlocked this critical pathway. By reducing cancer cell fitness, triggering intrinsic apoptosis, and engaging the immune system to clear residual tumor cells, LRK-4189 has the potential to overcome the limitations of earlier therapies. We're excited to advance this promising therapy to the clinic later this year.' According to the American Cancer Society, in the United States, approximately 150,000 cases of CRC are diagnosed annually, with MSS CRC accounting for about 85% of all CRC cases. About LRK-4189 LRK-4189 is an orally bioavailable, selective degrader of PIP4K2C with subnanomolar potency in primary human cells. LRK-4189-mediated degradation of PIP4K2C leads to intrinsic cancer cell death and activates interferon signaling, triggering multiple killing mechanisms in difficult-to-treat MSS CRC cells. In vivo, LRK-4189 demonstrates dose dependent PKPD with single agent efficacy in multiple models of CRC and synergy with first-line standard of care chemotherapy. In primary human CRC patient-derived spheroids, 50% of patient samples respond to LRK-4189 with a preferential response in MSS CRC, which compares favorably to benchmark cetuximab in the same platform (35%). Cetuximab may be either a first- or second-line treatment in people with RAS wild type CRC. LRK-4189 has completed IND-enabling studies and expects to initiate a Phase 1 clinical trial in Q4 2025. About Larkspur Biosciences Larkspur Biosciences is pioneering a new wave in cancer therapy that destroys tumors by targeting cancer cell fitness. Larkspur develops therapies that decrease cancer cell fitness and sensitizes the cells to intrinsic and immune-driven mechanisms of killing. The company is advancing first-in-class programs that target the adaptations cancer cells use to proliferate, invade tissue, and escape the immune system. LarkX, the company's proprietary bioinformatics platform, couples machine learning with tumor genetics to discover cancer cell fitness pathways that originate in the tumor and enrich clinical strategies for potential responders to its therapies across multiple types of cancer. Larkspur's founders include Lewis C. Cantley, PhD, professor of medicine at Dana-Farber Cancer Institute, professor of cell biology at Harvard Medical School; Vijay K. Kuchroo, DVM, PhD, professor of neurology at Harvard Medical School, senior scientist at Brigham and Women's Hospital; and Nathanael Gray, PhD, professor of chemical and systems biology at Stanford University. Visit us at and follow us on LinkedIn and X. Media Contact:Dan BoyleScientPRdan@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Hepsiburada Submits Amendment to 6-K
ISTANBUL, Aug. 20, 2025 (GLOBE NEWSWIRE) -- On August 15, 2025, D-MARKET Elektronik Hizmetler ve Ticaret Anonim Şirketi (the 'Company') furnished to the Securities and Exchange Commission a Form 6-K (the 'Original Form 6-K') containing certain exhibits relating to the Company's Annual General Assembly Meeting of Shareholders for, and with respect to, the financial year 2024, to be held on September 15, 2025. This Amendment No. 1 to the Original Form 6-K amends the Original Form 6-K solely for the purpose of amending and restating Exhibit 99.4 (Board of Directors' Annual Report for 2024) in its entirety, due to an inadvertent clerical error contained in the version included in the Original Form 6-K. Except as described above, the Original Form 6-K remains unchanged. About Hepsiburada Hepsiburada is a leading e-commerce technology platform in Türkiye, operating through a hybrid model that combines first-party direct sales (1P) and a third-party marketplace (3P) with approximately 100 thousand its vision of leading the digitalization of commerce, Hepsiburada serves as a reliable, innovative and purpose-driven companion in consumers' daily lives. Hepsiburada's e-commerce platform offers a broad ecosystem of capabilities for merchants and consumers including last-mile delivery, fulfilment services, advertising solutions, cross-border sales, payment services and affordability solutions. Hepsiburada's integrated fintech platform, Hepsipay, provides secure payment solutions, including digital wallets, general-purpose loans, buy now pay later (BNPL) and one-click checkout, enhancing shopping convenience for consumers across online and offline while driving higher sales conversions for its founding in 2000, Hepsiburada has been purpose-driven, leveraging its digital capabilities to empower women in the Turkish economy. In 2017, Hepsiburada launched the 'Technology Empowerment for Women Entrepreneurs' program, which has supported approximately 65 thousand female entrepreneurs across Türkiye in reaching millions of customers. Investor Relations Contactir@ Media Contactcorporatecommunications@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Onco360 adds Modeyso™ (dordaviprone) to portfolio of Oncology and Rare Cancer therapies as a National Specialty Pharmacy Provider
LOUISVILLE, Ky., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation's leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Jazz Pharmaceuticals for Modeyso™ (dordaviprone). It is indicated for the treatment of adult and pediatric patients one year of age and older with diffuse midline glioma harboring an H3 K27M-mutation with progressive disease following prior therapy.1 This indication was approved based on five open-label, non-randomized clinical trials conducted in the U.S. (ONC006 [NCT02525692], ONC013 [NCT03295396], ONC014 [NCT03416530], ONC016 [NCT05392374], and ONC018 [NCT03134131]).1 'Onco360 is grateful for the opportunity to add Modeyso™ to our expansive portfolio of cancer and rare disease therapies as the first and only FDA-approved treatment for pediatric and adult patients with diffuse midline glioma,' said Benito Fernandez. 'We are proud and humbled to be part of this innovative treatment in support of patients, caregivers and families impacted by this devastating disease.' Dordaviprone is a protease activator of the mitochondrial caseinolytic protease P (ClpP) and inhibits dopamine D2 receptor (DRD2). In vitro, dordaviprone activates the integrated stress response, induces apoptosis, and alters mitochondrial metabolism, leading to restored histone H3 K27 trimethylation in H3 K27M-mutant diffuse glioma.1 The efficacy of Modeyso was evaluated in an integrated efficacy population of 50 adult and pediatric patients with recurrent H3 K27M-mutant diffuse midline glioma enrolled across five open-label, non-randomized clinical trials.1 The primary outcome was overall response rate (ORR) of 22% (95% CI: 12,36). The trial also demonstrated a duration of response of 10.3 months (95% CI: 7.3, 15.2) with 73% maintaining their response for at least six months and 27% for at least 12 months.1 Dordaviprone demonstrated manageable safety and tolerability adverse events. The most common adverse reactions (≥20 %; all causality) experienced with dordaviprone were fatigue, headache, nausea, vomiting, and musculoskeletal pain.1 Please see the full Prescribing Information for Modeyso. About Onco360 Oncology Pharmacy:Onco360 is the nation's largest independent Oncology Pharmacy and clinical support services company. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC-, and ACHC-accredited Oncology Pharmacies. Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. For more information about Onco360, please visit Media Contact: Benito Fernandez, Chief Commercial References:1Modeyso™ (Dordaviprone) [Package Insert]. Palo Alto, CA. Jazz Pharmaceuticals. in to access your portfolio